ArticleScientific reports2025
Preclinical assessment of anti-arthritic activity of methanolic extract from processed Plumbago zeylanica roots.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ayurveda, a traditional Indian system of medicine, advocates the use of processed Plumbago zeylanica L. roots for managing inflammatory and rheumatic conditions. However, scientific evidence supporting its anti-arthritic potential remains unexplored. Our preliminary in vitro and in silico studies demonstrated potent anti-inflammatory activities in the methanolic extract of the processed root. Hence, this study aimed to investigate the pharmacological activities of the methanolic extract of processed roots in Freund's Complete Adjuvant (FCA)-induced rheumatoid arthritis in rats. Rheumatoid arthritis was induced in the rats by intra-articular injection of FCA in right paw on day 0, and treatment of prednisolone and different doses of Plumbago zeylanica methanolic extract (PZME) was given from day 1 to 28. Throughout the study, behavioral and physical arthritis parameters were evaluated, while biochemical serum levels of COX-2, inflammatory markers, and oxidative stress parameters were measured at the study's endpoint, and tibiotarsal joints were subjected to microscopic studies for histological evaluation. PZME treatment significantly attenuated FCA-induced rheumatoid arthritis, evidenced by reduced paw volume, joint diameter, and improved behavioral parameters (gait, weight-bearing). PZME also decreased serum levels of inflammatory markers (TNF-α, IL-6, RF, CRP), oxidative stress parameters (TBARS, catalase), and COX-2 expression. Histological analysis confirmed reduced synovial hyperplasia and cartilage erosion. LC-MS/MS analysis identified several phytoconstituents, which may contribute to the observed effects. In conclusion, the study demonstrates that the methanolic extract of P. zeylanica roots possesses potent anti-arthritic properties. This effect is likely due to its ability to reduce inflammation by inhibiting pro-inflammatory cytokines and oxidative stress, as well as decreasing COX-2 expression. However, further research is needed to elucidate precise molecular mechanisms, identification of bioactive phytoconstituents and assess long-term safety before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.